Management of acute myocardial infarction in intensive care units in 1995: a nationwide French survey of practice and early hospital results.

[1]  P. Sritara,et al.  Reduced in-hospital mortality from acute myocardial infarction with general adoption of thrombolytic treatment in the North West Thames health region 1979-1991. , 1995, British heart journal.

[2]  K. Swedberg,et al.  Declining hospital mortality in acute myocardial infarction. , 1994, European heart journal.

[3]  J Col,et al.  Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. , 1995, Circulation.

[4]  H. Ueshima,et al.  Declining mortality from ischemic heart disease and changes in coronary risk factors in Japan, 1956-1980. , 1987, American journal of epidemiology.

[5]  Sarah Parish,et al.  Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.

[6]  H. White,et al.  Comparison of effects of thrombolytic therapy on left ventricular function in patients over with those under 60 years of age. , 1991, The American journal of cardiology.

[7]  P. Kudenchuk,et al.  Hospital mortality in acute myocardial infarction in the era of reperfusion therapy (the Myocardial Infarction Triage and Intervention Project). , 1993, The American journal of cardiology.

[8]  R. Collins,et al.  British Heart Foundation surveys (1987 and 1989) of United Kingdom treatment policies for acute myocardial infarction. , 1991, British heart journal.

[9]  Johan Herlitz,et al.  Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[10]  David Hunt,et al.  ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION , 1992 .

[11]  P. Marques-Vidal,et al.  Evolution à long terme de la prescription médicamenteuse chez 174 patients atteints d'infarctus du myocarde suivis pendant 4,5 ans (étude DEVENIR) , 1996 .

[12]  J. Ruidavets,et al.  Trends in acute myocardial infarction prognosis and treatment in southwestern France between 1985 and 1990 (the MONICA Project-Toulouse). , 1995 .

[13]  G. Hanania,et al.  [Therapeutic strategies in acute myocardial infarction. Results of STIM 93 registry]. , 1996, Archives des maladies du coeur et des vaisseaux.

[14]  J. Gurwitz,et al.  Coronary thrombolysis for the elderly? , 1991, JAMA.

[15]  M S Golden,et al.  Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. , 1980, The New England journal of medicine.

[16]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.,et al.  EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.

[17]  D. Arveiler,et al.  Prise en charge thérapeutique de l'infarctus du myocarde : évolution dans le projet MONICA-France entre 1985 et 1991 , 1996 .

[18]  Y. Ohtsuki,et al.  ISOLATION OF HTLV-I FROM CEREBROSPINAL FLUID OF A PATIENT WITH MYELOPATHY , 1986, The Lancet.

[19]  C. Peterson.  A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction: Grines CL, Browne KF, Marco J, et al. N Engl J Med 328:673–679 Mar 1993 , 1993 .

[20]  J O'Keefe,et al.  A Comparison of Immediate Angioplasty with Thrombolytic Therapy for Acute Myocardial Infarction , 1993 .

[21]  W. O’Neill,et al.  Regional variation across the United States in the management of acute myocardial infarction. , 1995, The New England journal of medicine.

[22]  G. Murray,et al.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .

[23]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[24]  Raymond C. Schneider,et al.  ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.

[25]  C. Fry,et al.  Science of urinary incontinence Report of a Meeting of Physicians and Scientists, University College London , 1994, The Lancet.

[26]  J. Rouleau,et al.  Myocardial infarction patients in the 1990s--their risk factors, stratification and survival in Canada: the Canadian Assessment of Myocardial Infarction (CAMI) Study. , 1996, Journal of the American College of Cardiology.

[27]  G. Lamas,et al.  Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. , 1992, The New England journal of medicine.

[28]  L Pilote,et al.  Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. , 1995, The New England journal of medicine.

[29]  E. Aliot,et al.  A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. , 1995, The New England journal of medicine.

[30]  M. Gheorghiade,et al.  Decline in the rate of hospital mortality from acute myocardial infarction: impact of changing management strategies. , 1996, American heart journal.

[31]  M. Møller,et al.  Residual myocardial ischaemia in first non-Q versus Q wave infarction: maximal exercise testing and ambulatory ST-segment monitoring. , 1993, European heart journal.

[32]  J. Berning,et al.  Early estimation of risk by echocardiographic determination of wall motion index in an unselected population with acute myocardial infarction. , 1990, The American journal of cardiology.

[33]  J. Boissel,et al.  [Drug prescription in myocardial postinfarction: results of the EPPI (étude de prescription postinfarctus). A French cooperative study]. , 1990, Archives des maladies du coeur et des vaisseaux.

[34]  G. Tognoni,et al.  Acute Myocardial Infarction Treatments in 58 Italian Hospitals: A Drug Utilization Survey , 1995, The Annals of pharmacotherapy.

[35]  A. Folsom,et al.  Recent trends in acute coronary heart disease--mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. , 1996, The New England journal of medicine.

[36]  P. Kligfield.  Primary angioplasty in myocardial infarction. , 1995, British heart journal.

[37]  C. Osmond.  Coronary heart disease mortality trends in England and Wales, 1952-1991. , 1995, Journal of public health medicine.

[38]  T. Wilt,et al.  Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. , 1995, The American journal of cardiology.

[39]  S. Yusuf,et al.  Effects of beta-blockers and calcium channel blockers in acute myocardial infarction. , 1993, European heart journal.

[40]  E. Veys,et al.  Letter: HL-A and infective sacroileitis. , 1974, Lancet.

[41]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  GISSI-3: effects of lisiriopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction , 1994, The Lancet.

[42]  U. Goldbourt,et al.  Trends in coronary heart disease mortality and related factors in Israel. , 1985, Cardiology.

[43]  B. Modan,et al.  Twenty-five—year mortality rate decrease in patients in Israel with a first episode of acute myocardial infarction , 1995 .

[44]  T. Bowker,et al.  A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). , 1996, Heart.

[45]  A. Dobson,et al.  Declining mortality from ischemic heart disease and cerebrovascular disease in Australia. , 1989, American journal of epidemiology.

[46]  European Cooperative Study Group,et al.  Translation of clinical trials into practice: a European population-based study of the use of thrombolysis for acute myocardial infarction , 1996, The Lancet.

[47]  D. Brand,et al.  Cardiologists' practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction. , 1995, Journal of the American College of Cardiology.

[48]  R. M. Rubison,et al.  Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. , 1994, Circulation.

[49]  L. Goldman,et al.  Impact of a public campaign on pre-hospital delay in patients reporting chest pain. , 1996, Heart.